Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 21 for “"Leflunomide"”.
-
Individualisation of leflunomide dosing in rheumatoid arthritis patients
Historically, leflunomide has been a second-line disease modifying anti-rheumatic drug (DMARD), initiated in those who fail to respond to methotrexate-based therapies. Nowadays, those who fail to respond to leflunomide tend to progress to expensive biological agents. Leflunomide’s therapeutic …
-
The Effectiveness of Leflunomide Etanercept and Infliximab in the Treatment of Rheumatoid Arthritis:a systematic review
… (Enbrel®) and infliximab (Remicade®), and leflunomide (Arava®) that targets proliferating T-cells offer a novel approach. With the approval of marketing these drugs by the Food and Drug Administration (FDA), the safety and efficacy data for these new disease modifying anti-rheumatic agents …
-
Quantitative analysis of the effect of leflunomide on neural crest cell gene regulation during early embryonic development
… fully understood. The small molecule compound leflunomide inhibits neural crest development. Leflunomide’s mode of action is to inhibit pyrimidine biosynthesis, thereby, preventing RNA transcription. Neural crest genes are actively transcribed and like many embryonic stem cells and tumour cells …
-
A chemical genetic approach to identify new treatments for melanoma
… identified that the already FDA approved drug leflunomide used for rheumatoid arthritis patients also holds potential therapeutic value in treating melanoma. This thesis shows the results of a new successful chemical genetic and cell based viability screen of the NCI Diversity set II library. …
-
Transcriptional Elongation is Important for Neural Crest Development
… 2]. Here I show that the small molecule compound leflunomide is able to inhibit neural crest specification genes. Leflunomide exerts its actions by inhibiting pyrimidine synthesis and therefore RNA transcription [4]. Neural crest genes are thought to be actively transcribed and like many embryonic …
-
Assessing the cost-effectiveness of tumor necrosis factor inhibitors and prescribing practices of rheumatologists in patients with rheumatoid arthritis
… plus MTX, (3) infliximab plus MTX, (4) leflunomide plus MTX, and (5) standard therapy of MTX. A hypothetical cohort of 10,000 55-year old women was evaluated using Monte Carlo simulation. The study was conducted from a societal perspective. The main outcome measures were net gains in …
-
Sarkoidozė. Literatūros apžvalga ir klinikinis atvejis /
… methotrexate, azathioprine, leflunomide, mycophenolate mofetil and, in rare cases, tumour necrosis factor inhibitors may be used. The prognosis of sarcoidosis is usually favourable, with spontaneous remission in the majority of patients and a 5-year survival rate of over 90%. …
-
Canine pharmacodynamic assays: applications in immune-mediated disease
… and the active metabolites of azathioprine and leflunomide) on lymphocyte proliferation in individual dogs. The first-phase of this project focused on peripheral blood mononuclear cells to evaluate canine T lymphocyte proliferation and the concentration of all four immunosuppressants that would …
-
Factors associated with the initiation of biologic disease modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis
… (680.2±158.7) users and similar to leflunomide users (541.6±286.5; p<0.0001). There were no significant differences in time to initiation between non-biologic DMARD mono vs. dual therapy. Younger age, glucocorticoid use, methotrexate user (vs. sulfasalazine, hydroxychloroquine …
-
Evaluating key performance indicators of the process of care in juvenile idiopathic arthritis
… for patients receiving methotrexate and leflunomide ranged from 76% to 90% after the first month. ConclusionAlthough the KPIs are feasible to measure in routinely collected data, there is an opportunity for improving the consistency of documentation. Having an active system of monitoring …
-
Measurement of physiological variables by dynamic Gd-DTPA enhanced MRI
… was detected in 17 patients treated with leflunomide four months after the start of treatment whilst it remained unchanged in 17 patients treated with methotrexate in a randomised controlled study of established RA of the knee joint. The results obtained in this work indicate that the …
-
Targeting anti-androgen resistance in prostate cancer using preclinical models with physiological nutrient levels
… (UCPH-101) in combination with inhibiting DHODH (Leflunomide) to prevent pyrimidine synthesis from aspartate was effective against prostate cancer cells in Plasmax in vitro. While we identified a previously unreported anti-androgen resistance mechanism involving aspartate that could be targeted …
-
Studies of cocrystal-excipient interaction by a combination of experimental and computational approaches.
… active pharmaceutical ingredient (API), Leflunomide (LEF). Novel multi-component systems, both pharmaceutically and non-pharmaceutically acceptable, of LEF have been synthesised. Their multi-component nature was confirmed, and each system has been comprehensively characterised using X-ray …
-
Identification of monoamine oxidase inhibitors using a molecular modelling approach
… = 23.2 μM for MAO-A and 48.3 μM for MAO-B) and leflunomide (IC50 = 19.1μM for MAO-A and 13.7 μM for MAO-B). The MAO inhibitory properties of caffeine and esomeprazole were further investigated. The reversibility of MAO inhibition by caffeine and esomeprazole were determined by dialysis and …
-
Η επίδραση των νεότερων βιολογικών-τροποποιητικών της νόσου αντιρευματικών φαρμάκων (DMARDs) στους παράγοντες κινδύνου για την εμφάνιση καρδιαγγειακής νόσου σε ασθενείς με ρευματοειδή αρθρίτιδα
… Patients were already receiving MTX or (Leflunomide) LFN and prednisone at constant doses throughout the study. They started taking a biological agent after a failure of clinical and laboratory improvement with a combination of at least two csDMARDs. Serum lipid levels of patients were …
-
Γενετική ρύθμιση της υπέρτασης σε ασθενείς με ρευματοειδή αρθρίτιδα
… anti?rheumatic drugs (particularly leflunomide and cyclosporin, and glucocorticosteroids); iv) genetic predisposition, which is thought to account for 30 to 50% of essential hypertension.
-
Synthesis, Characterisation and Applications of Fluorinated Amphiphiles and their Self-Assemblies
… and shown to encapsulate the fluorinated drug Leflunomide with high efficiency (62 ± 3%), resulting in a twelve-fold increase in solubility. A systematic comparison of fluorinated and hydrogenated amphiphiles revealed strong effects of tail chemistry on self-assembly and drug loading, as …
-
Routineeinsatz von Leflunomid bei Rheumatoider Arthritis
Die Rheumatoide Arthritis (RA) ist eine multifaktoriell bedingte Autoimmunerkrankung, die durch entzündlichen Gelenksbefall charakterisiert ist. Unter fehlender oder ungenügender therapeutischer Intervention nimmt die Erkrankung einen progressiven Verlauf, der zu Gelenkdestruktionen und damit zu …
-
Burden of rheumatoid arthritis in the private health sector : medicine cost and comorbidities
… (8.9%), celecoxib (7.2%), diclofenac (3.8%), leflunomide (3.2%), etoricoxib (3.0%), naproxen/esomeprazole (1.3%), betamethasone (1.2%) and methylprednisolone (1.2%), these drugs accounting for only 34.7% of the total annual medicine cost. Rheumatoid arthritis patients with coexisting …
-
Inzidente neuropathische Symptome unter Behandlung der rheumatoiden Arthritis mit Leflunomid
Mit einer Prävalenz von 0,5% bis 0,8% unter der erwachsenen Bevölkerung ist die rheumatoide Arthritis die wichtigste entzündlich-rheumatische Gelenkerkrankung in Deutschland. Bei konsequent frühzeitigem Einsatz immunsuppressiver Therapien können hohe klinische Remissionsraten erreicht werden. …
Page 1 of 2